Acute Stroke Treatment with Atorvastatin and Irbesartan
A placebo controlled study to test the effectiveness of atorvastatin and irbesartan on infarct size, cerebral perfusion, cerebral response to ischaemia and clinical outcome in acute ischaemic stroke
University of Western Australia
200 participants
May 1, 2005
Interventional
Conditions
Summary
The study aims to examine the effect of early treatment of acute ischaemic stroke with an ATRA and statin on surrogate markers of clinical outcome comprising the local response to ischaemia, cerebral blood flow, infarct growth and recurrent cardiovascular events.
Eligibility
Exclusion Criteria1
- Hypotension: Blood pressure less than 100mmHg systolic or 70mmHg diastolic. Hypertension (>220 mmHg) or clinical imperative to lower blood pressure. Hyperkalaemia: >5.5 mmol/L. Finger prick or laboratory blood sugar level > 13 mmol/L at baseline. Acute comorbid condition (such as myocardial ischaemia or sepsis). Active liver disease or unexplained elevation in transaminases. Already treated with ATRA, statin or more than one of an ACE inhibitor, non steroidal anti-inflammatory, potassium sparing diuretic, potassium salt or cyclosporin. Premenopausal female. Renal impairment (defined as creatinine >120 umol/L). History of sensitivity to statins, ATRA or contrast. Haemorrhage seen on initial CT.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
30 days Atorvastatina 80 mg and Irbesartan 150 mg 2x2 factorial design
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000170628